Robert M. Stoekenbroek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Robert M. Stoekenbroek has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
D.T. Ubbink
Department of Surgery, Academic Medical Center, P.O. Box 22660, 1100 DD Amsterdam, The Netherlands
2 shared publicationsM.J.W. Koelemay
Department of Surgery, Academic Medical Center, P.O. Box 22660, 1100 DD Amsterdam, The Netherlands
2 shared publicationsA. van Den Brink
Department of Surgery, Academic Medical Center, Amsterdam, The Netherlands; Department of Hyperbaric Medicine, Academic Medical Center, Amsterdam, The Netherlands
1 shared publicationA.H. Zwinderman
Academic Medical Centre, Department of Clinical Epidemiology, Biostatistics & Bioinformatics, Amsterdam, The Netherlands
1 shared publicationB.A. Hutten
Academic Medical Centre, Department of Clinical Epidemiology, Biostatistics & Bioinformatics, Amsterdam, The Netherlands
1 shared publicationC.J. Currie
School of Medicine, Cardiff University, Department of Medicine, Cardiff, United Kingdom
1 shared publication
Latest Publications
- 7 April 2018
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (14) , 1169-1171
Homozygous familial hypercholesterolaemia: light at the end of the tunnel
- 7 April 2018
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 39 (14) , 1169-1171
Homozygous familial hypercholesterolaemia: light at the end of the tunnel
- Open Access
- 13 April 2017
- Published by Springer Nature in Diabetologia
- Vol. 60 (7) , 1271-1275
How common are foot problems among individuals with diabetes? Diabetic foot ulcers in the Dutch population
Aims/hypothesis Contemporary data on diabetic foot ulcer prevalence are scarce. Most studies were conducted in the 1990s, reporting incidence rates of 1.9–2.6%. Since then the prevalence of diabetes has doubled and the organisation of diabetes care has undergone major changes. Up-to-date data that quantify the occurrence of diabetic foot ulcers are required and could serve as baseline measures for future studies. Methods Individuals with diabetes (n = 81,793) were identified from the NIVEL (Netherlands institute for health services research) Primary Care Database, which contains data for standardised routine care and is representative of the Dutch population. The annual incidence rates of ulcers and other foot abnormalities were calculated using data collected between 2010 and 2013. To account for inaccuracies, incidence rates were calculated using: (1) only individuals with a documented foot examination; (2) all individuals; and (3) individuals with explicit documentation of present/absent foot ulceration. Results There were 412 individuals with documented ulceration during the registration period (0.50%). The annual incidence rate of foot ulcers was 0.34% (range 0.22–1.08%). Of those individuals with a documented foot examination, 14.6% had absent pedal pulsations, 17.3% had neuropathy and 10.1% had callus/pressure marks. Conclusions/interpretation The annual incidence rate of foot ulcers in the current study was lower than previously reported. This observation could reflect the efficacy of screening practices and an increased awareness among professionals and patients. Nevertheless, approximately one in every five diabetic individuals had at least one identifiable risk factor on foot examination. This signifies the importance of preventive screening.
- 13 April 2017
- Published by Springer Nature in Diabetologia
- Vol. 60 (7) , 1271-1275
Open AccessHow common are foot problems among individuals with diabetes? Diabetic foot ulcers in the Dutch population
Aims/hypothesis Contemporary data on diabetic foot ulcer prevalence are scarce. Most studies were conducted in the 1990s, reporting incidence rates of 1.9–2.6%. Since then the prevalence of diabetes has doubled and the organisation of diabetes care has undergone major changes. Up-to-date data that quantify the occurrence of diabetic foot ulcers are required and could serve as baseline measures for future studies. Methods Individuals with diabetes (n = 81,793) were identified from the NIVEL (Netherlands institute for health services research) Primary Care Database, which contains data for standardised routine care and is representative of the Dutch population. The annual incidence rates of ulcers and other foot abnormalities were calculated using data collected between 2010 and 2013. To account for inaccuracies, incidence rates were calculated using: (1) only individuals with a documented foot examination; (2) all individuals; and (3) individuals with explicit documentation of present/absent foot ulceration. Results There were 412 individuals with documented ulceration during the registration period (0.50%). The annual incidence rate of foot ulcers was 0.34% (range 0.22–1.08%). Of those individuals with a documented foot examination, 14.6% had absent pedal pulsations, 17.3% had neuropathy and 10.1% had callus/pressure marks. Conclusions/interpretation The annual incidence rate of foot ulcers in the current study was lower than previously reported. This observation could reflect the efficacy of screening practices and an increased awareness among professionals and patients. Nevertheless, approximately one in every five diabetic individuals had at least one identifiable risk factor on foot examination. This signifies the importance of preventive screening.
- Open Access
- 12 October 2015
- Published by Springer Nature in BMC Medicine
- Vol. 13 (1) , 1-6
PCSK9 inhibition: the way forward in the treatment of dyslipidemia
Barely a decade after the discovery of the gene encoding proprotein convertase subtilisin/kexin type 9 (PCSK9) and its recognition as a key player in cholesterol metabolism, PCSK9 inhibition is now considered an exciting approach in the reduction of residual risk of cardiovascular disease. The progress from PCSK9 discovery to the development of targeted treatment has been unprecedented in terms of scale and speed. The first suggestion of a link between PCSK9 and hypercholesterolemia was published in 2003; a decade later, two meta-analyses of clinical trials comparing anti-PCSK9 treatment to placebo or ezetimibe, including >10,000 hypercholesterolemic individuals, were published. Currently, three PCSK9 inhibitors are being evaluated in clinical outcome trials and the results will determine the future of these lipid-lowering therapies by establishing their clinical efficacy in terms of cardiovascular event reduction, safety, and the consequences of prolonged exposure to very low levels of LDL-cholesterol. Irrespective of their outcomes, the exceptionally rapid development of these drugs exemplifies how novel technologies, genetic validation, and rapid clinical progression provide the tools to expedite the development of new drugs.
- 12 October 2015
- Published by Springer Nature in BMC Medicine
- Vol. 13 (1) , 1-6
Open AccessPCSK9 inhibition: the way forward in the treatment of dyslipidemia
Barely a decade after the discovery of the gene encoding proprotein convertase subtilisin/kexin type 9 (PCSK9) and its recognition as a key player in cholesterol metabolism, PCSK9 inhibition is now considered an exciting approach in the reduction of residual risk of cardiovascular disease. The progress from PCSK9 discovery to the development of targeted treatment has been unprecedented in terms of scale and speed. The first suggestion of a link between PCSK9 and hypercholesterolemia was published in 2003; a decade later, two meta-analyses of clinical trials comparing anti-PCSK9 treatment to placebo or ezetimibe, including >10,000 hypercholesterolemic individuals, were published. Currently, three PCSK9 inhibitors are being evaluated in clinical outcome trials and the results will determine the future of these lipid-lowering therapies by establishing their clinical efficacy in terms of cardiovascular event reduction, safety, and the consequences of prolonged exposure to very low levels of LDL-cholesterol. Irrespective of their outcomes, the exceptionally rapid development of these drugs exemplifies how novel technologies, genetic validation, and rapid clinical progression provide the tools to expedite the development of new drugs.
- 1 June 2015
- Published by Elsevier in Atherosclerosis
- Vol. 240 (2) , 318-323
High daily insulin exposure in patients with type 2 diabetes is associated with increased risk of cardiovascular events
- 1 June 2015
- Published by Elsevier in Atherosclerosis
- Vol. 240 (2) , 318-323
High daily insulin exposure in patients with type 2 diabetes is associated with increased risk of cardiovascular events
- 1 February 2015
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 49 (2) , 192-198
Hide and Seek: Does the Toe-brachial Index Allow for Earlier Recognition of Peripheral Arterial Disease in Diabetic Patients?
- 1 February 2015
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 49 (2) , 192-198
Hide and Seek: Does the Toe-brachial Index Allow for Earlier Recognition of Peripheral Arterial Disease in Diabetic Patients?
- 1 June 2014
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 47 (6) , 647-655
Hyperbaric Oxygen for the Treatment of Diabetic Foot Ulcers: A Systematic Review
- 1 June 2014
- Published by Elsevier in European Journal of Vascular and Endovascular Surgery
- Vol. 47 (6) , 647-655
Hyperbaric Oxygen for the Treatment of Diabetic Foot Ulcers: A Systematic Review
- 1 March 2014
- Vol. 24, 99-111
Systemic wound care: a meta-review of cochrane systematic reviews.
Wound care is a classic example of a surgical realm with a great variation in care. The diversity in wounds and wound treatments, the limited amount of convincing evidence, and the diverging opinions among doctors and nurses involved in wound care contribute to this undesirable variation in care. For chronic wounds, such as arterial or venous ulcers, pressure sores, and diabetic foot ulcers, but also for acute wounds after surgery or trauma, international and national guidelines provide recommendations on diagnostic procedures and treatment options, but rely mostly on expert opinion. We present the available evidence from Cochrane systematic reviews for the systemic treatment (i.e., not prevention) of patients with wounds, as opposed to topical wound treatments. This evidence shows: - Venous ulcers: High-compression therapy is the classic and evidence-based treatment for treating venous ulcers. Oral pentoxifylline promotes ulcer healing with and without compression therapy. Oral zinc is not effective to heal venous ulcers. - Acute wounds: Recombinant human growth hormone accelerates healing of large burn wounds and donor sites, while high-carbohydrate feeding might reduce the risk of pneumonia. Linezolid is more effective than vancomycin for treating skin and soft tissue infections. Hyperbaric oxygen may help heal crush wounds and skin grafts. Therapeutic touch does not heal acute wounds. - Pressure sores: Air-fluidized and some low-tech devices appear effective for treating existing pressure ulcers. Oral zinc, protein, or vitamin C supplements seem ineffective. Also, evidence is lacking on the effectiveness of repositioning regimes as a treatment option. - Diabetic ulcers: Hyperbaric oxygen therapy and pressure-relieving devices may improve healing rates. - Arterial ulcers: Prostanoids and spinal cord stimulation may be effective in healing ischemic ulcers. Thus, fortunately, some high-level evidence exists for various local and systemic interventions in wound care. Caregivers should be aware of, and apply, the strongest evidence available. Only when all stakeholders (patients, physicians, wound care nurses, but also manufacturers and buyers) implement this available evidence will optimum quality of care for patients with wounds be ensured.
- 1 March 2014
- Vol. 24, 99-111
Systemic wound care: a meta-review of cochrane systematic reviews.
Wound care is a classic example of a surgical realm with a great variation in care. The diversity in wounds and wound treatments, the limited amount of convincing evidence, and the diverging opinions among doctors and nurses involved in wound care contribute to this undesirable variation in care. For chronic wounds, such as arterial or venous ulcers, pressure sores, and diabetic foot ulcers, but also for acute wounds after surgery or trauma, international and national guidelines provide recommendations on diagnostic procedures and treatment options, but rely mostly on expert opinion. We present the available evidence from Cochrane systematic reviews for the systemic treatment (i.e., not prevention) of patients with wounds, as opposed to topical wound treatments. This evidence shows: - Venous ulcers: High-compression therapy is the classic and evidence-based treatment for treating venous ulcers. Oral pentoxifylline promotes ulcer healing with and without compression therapy. Oral zinc is not effective to heal venous ulcers. - Acute wounds: Recombinant human growth hormone accelerates healing of large burn wounds and donor sites, while high-carbohydrate feeding might reduce the risk of pneumonia. Linezolid is more effective than vancomycin for treating skin and soft tissue infections. Hyperbaric oxygen may help heal crush wounds and skin grafts. Therapeutic touch does not heal acute wounds. - Pressure sores: Air-fluidized and some low-tech devices appear effective for treating existing pressure ulcers. Oral zinc, protein, or vitamin C supplements seem ineffective. Also, evidence is lacking on the effectiveness of repositioning regimes as a treatment option. - Diabetic ulcers: Hyperbaric oxygen therapy and pressure-relieving devices may improve healing rates. - Arterial ulcers: Prostanoids and spinal cord stimulation may be effective in healing ischemic ulcers. Thus, fortunately, some high-level evidence exists for various local and systemic interventions in wound care. Caregivers should be aware of, and apply, the strongest evidence available. Only when all stakeholders (patients, physicians, wound care nurses, but also manufacturers and buyers) implement this available evidence will optimum quality of care for patients with wounds be ensured.